Maintaining a bullish rating, Macquarie has a target of Rs 50 per share on the stock. The brokerage believes that promoter infusion may lead to relief rally in the stock. It says that post promoter infusion debt will come down by 10 percent as FY15 net debt stands at Rs 5500 crore.